Recent research indicates that colon cancer patients with circulating tumor DNA post-surgery may improve their survival likelihood with daily celecoxib use. Celecoxib, a COX-2 inhibitor, significantly ...

A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham ...

It's more expensive. Sold only as a prescription, brand-name drug, celecoxib can easily cost $130 or more a month for a standard dose, compared with about $25 for the generic, over-the-counter ...

The study group received a single 400 mg dose of celecoxib, one hour before surgery, and 200 mg of celecoxib every 12 hours for five days, along with patient-controlled analgesic (PCA) morphine.

Celecoxib was the first to reach the market, gaining approval from the Food and Drug Administration (FDA) Dec. 31, 1998. A second COX-2 inhibitor, rofecoxib (Vioxx) became available the following May.

A recent analysis from a randomized clinical trial conducted by researchers at the Dana-Farber Brigham Cancer Center ...

The Alliance for Clinical Trials in Oncology today announced the results of a data analysis from a randomized phase III clinical trial involving patients with stage III colon cancer, which found that ...

Celebrex is not as dangerous as Vioxx. 200mgs a day is the common dosage of celebex. Though this dosage has never been associated with heart diseases or attacks, it does carry some risk when given ...